Recent Security Class Actions
Aclaris Therapeutics Inc. Common Stock (NASDAQ: ACRS)
Company Name:Aclaris Therapeutics Inc. Common Stock
Stock Symbol:NASDAQ: ACRS
Class Period Start:05/08/2019
Class Period End (inclusive):08/12/2019
Filing Deadline:10/29/2019
According to the Complaint, Aclaris is a biopharmaceutical company that identifies, develops, and commercializes therapies to address unmet needs in medical and aesthetic dermatology and immunology. Its lead product ESKATA is a hydrogen peroxide topical solution that is FDAapproved to treat raised seborrheic keratosis, a common non-malignant tumor.
